SBIO: ALPS MEDICAL BREAKTHROUGHS ETF
ALPS MEDICAL BREAKTHROUGHS ETF (SBIO)
What this ETF is trying to do:
The ALPS Medical Breakthroughs ETF, or SBIO for short, aims to invest in companies that are making significant advancements in the medical field. This includes firms working on new treatments and technologies that could revolutionize healthcare.
What the numbers show:
• Current Price: $56.26
• Year-to-Date (YTD) Return: 9.84% (both price return and total return)
• One-Year Return: 41.18% (both price return and total return)
• Three-Year Return: 110.36% (price return), 118.27% (total return)
The ETF has shown strong performance over the past year and three years, with both its share prices and overall returns increasing significantly.
Income and Distribution Explanation:
SBIO does not pay regular distributions to investors. The distribution yield is currently zero percent, meaning there are no cash payouts from this fund.
NAV Erosion Explanation:
The ETF has a strong erosion score of 100, which means that according to the data provided, there is no evidence of price erosion or decline in value over time. This indicates that the share prices have been stable and growing without significant drops.
Pros:
• Strong Performance: SBIO has demonstrated robust returns over various periods.
• No NAV Erosion: The fund's performance shows stability with no signs of price erosion, which is reassuring for investors looking to preserve capital.
• Focus on Medical Breakthroughs: Investing in companies that are making significant advancements can be exciting and potentially rewarding.
Cons:
• No Distributions: Since SBIO does not pay out any distributions, the income generated from this ETF comes solely from its price appreciation. This might not suit investors looking for regular cash payouts.
Beginner Takeaway:
The ALPS Medical Breakthroughs ETF is a good choice for those interested in investing in companies that are making significant strides in medical research and development. It has shown strong performance over the past year and three years, with no signs of price erosion. However, it does not provide regular income through distributions, so investors should be prepared to rely on capital appreciation as their primary source of returns.
---
This report is purely educational and does not constitute financial advice. Always do your own research or consult a professional before making investment decisions.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 3.97% |
| 2 | ORUKA THERAPEUTICS INC | ORKA | 3.63% |
| 3 | TRAVERE THERAPEUTICS INC ORDINARY SHARES | TVTX | 3.44% |
| 4 | DIANTHUS THERAPEUTICS INC | DNTH | 3.19% |
| 5 | n/a | DFTX | 3.09% |
| 6 | VERADERMICS INC | MANE | 2.95% |
| 7 | EDGEWISE THERAPEUTICS INC | EWTX | 2.72% |
| 8 | ACADIA PHARMACEUTICALS INC | ACAD | 2.67% |
| 9 | RELAY THERAPEUTICS INC ORDINARY SHARES | RLAY | 2.41% |
| 10 | AMYLYX PHARMACEUTICALS INC | AMLX | 2.34% |